ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion
Open Access
- 13 June 2012
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 11 (1) , 65
Abstract
Background: Previous studies suggested that the RhoA/ROCK pathway may contribute to vascular complications in diabetes. The present study was designed to investigate whether ROCK inhibitor fasudil could prevent high glucose-induced monocyte-endothelial cells adhesion, and whether this was related to fasudil effects on vascular endothelial cell expression of chemotactic factors, vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1). Methods: HUVECs were stimulated with high glucose (HG) or HG + fasudil in different concentration or different time. Monocyte-endothelial cell adhesion was determined using fluorescence-labeled monocytes. The mRNA and protein expression of VCAM-1 and MCP-1 were measured using real-time PCR and western blot. The protein levels of RhoA, ROCKI and p-MYPT were determined using western blot analysis. ELISA was employed to measure the expression of soluble VCAM-1 and MCP-1 in cell supernatants and human serum samples. Results: Fasudil significantly suppressed HG-induced adhesion of THP-1 to HUVECs. Fasudil reduced Rho/ROCK activity (as indicated by lower p-MYPT/MYPT ratio), and prevented HG induced increases in VCAM-1 and MCP-1 mRNA and protein levels. Fasudil also decreased MCP-1 concentration in HUVEC supernatants, but increased sVCAM-1 shedding into the media. In human diabetic subjects, 2 weeks of fasudil treatment significantly decreased serum MCP-1 level from 27.9 ± 10.6 pg/ml to 13.8 ± 7.0 pg/ml (P < 0.05), while sVCAM-1 increased from 23.2 ± 7.5 ng/ml to 39.7 ± 5.6 ng/ml after fasudil treatment (P < 0.05). Conclusions: Treatment with the Rho/ROCK pathway inhibitor fasudil attenuated HG-induced monocyte-endothelial cell adhesion, possibly by reducing endothelial expression of VCAM-1 and MCP-1. These results suggest inhibition of Rho/ROCK signaling may have therapeutic potential in preventing diabetes associated vascular inflammation and atherogenesis.Keywords
This publication has 47 references indexed in Scilit:
- High-dose fasudil preserves postconditioning against myocardial infarction under hyperglycemia in rats: role of mitochondrial KATP channelsCardiovascular Diabetology, 2012
- A Novel RhoA/ROCK-CPI-17-MEF2C Signaling Pathway Regulates Vascular Smooth Muscle Cell Gene ExpressionJournal of Biological Chemistry, 2012
- RhoA/ROCK-dependent moesin phosphorylation regulates AGE-induced endothelial cellular responseCardiovascular Diabetology, 2012
- Activation of the ROCK1 Branch of the Transforming Growth Factor-β Pathway Contributes to RAGE-Dependent Acceleration of Atherosclerosis in Diabetic ApoE-Null MiceCirculation Research, 2010
- Molecular Insights and Therapeutic Targets for Diabetic Endothelial DysfunctionCirculation, 2009
- Statins inhibit Rho kinase activity in patients with atherosclerosisAtherosclerosis, 2009
- ROCK1 mediates leukocyte recruitment and neointima formation following vascular injuryJournal of Clinical Investigation, 2008
- Applications for ROCK kinase inhibitionCurrent Opinion in Cell Biology, 2008
- Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruptionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Intermittent high glucose enhances ICAM‐1, VCAM‐1, E‐selectin and interleukin‐6 expression in human umbilical endothelial cells in culture: the role of poly(ADP‐ribose) polymeraseJournal of Thrombosis and Haemostasis, 2004